Actively Recruiting
Preventing Blood Clots After Varicose Vein Treatments Using Blood Thinners in Adults
Led by Imperial College London · Updated on 2026-06-04
3175
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying people with varicose veins undergoing endovenous interventions, which are keyhole procedures performed inside the veins. These varicose veins are enlarged veins near the skin surface connected to deeper veins in the leg. The study aims to find out if medicines that reduce blood clots are helpful after these procedures, as blood clots can cause swelling, pain, and serious lung problems, and current clot prevention methods have uncertain benefits. Participants will be randomly assigned to one of three groups compression therapy alone, compression therapy plus a single dose of low molecular weight heparin LMWH at the time of the procedure, or compression therapy plus a single LMWH dose and an extended course of LMWH or a direct oral anticoagulant DOAC for at least 7 days. The medicines studied include dalteparin, tinzaparin, enoxaparin, rivaroxaban, apixaban, and dabigatran. Treatments will follow standard practice and manufacturer instructions. During the study, participants will be monitored for blood clots in the deep veins or lungs within 90 days after their varicose vein treatment. Assessments include imaging scans to confirm clots, quality of life questionnaires at 7 and 90 days, and evaluation of clot risk tools. Safety and cost-effectiveness will also be reviewed. Participants will be followed closely to track any clot-related events or other health changes for up to 90 days after treatment.
CONDITIONS
Brief Title
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Research Team
S
Sarah Whittley
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here